Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients

Sasanpour, Pegah; Sandoughdaran, Saleh; Mosavi-Jarrahi, Alireza; Malekzadeh, Mona

doi:10.22034/APJCP.2018.19.9.2423

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients

Document Type : Research Articles

Authors

¹ Department of Radiation Oncology, Shohada-e-Tajrish Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

² Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

³ Department of Epidemiology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

10.22034/APJCP.2018.19.9.2423

Abstract

Background: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant
chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pCR in Iranian breast cancer patients receiving NAC. Methods: A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between April 2012 and September 2016 at our institution was performed; 207 cases were evaluable for analysis. pCR was defined as having no residual invasive tumor in the breast surgical specimen removed following neoadjuvant therapy. Results: In univariate analysis, factors associated with pCR were age less than 35 years (p = 0.03), absence of Lymphovascular invasion (LVI) (p = 0.002) and negative hormone receptor status (p = 0.003). Hormone receptor status (P = 0.01; OR, 2.45; CI, 1.20 - 4.99) and LVI (P = 0.001; OR, 0.22; CI, 0.10 - 0.46) remained predictive variables in multivariate analysis after correction for the other variables. Conclusions: In conclusion, the results of this study suggests that presence of Lymphovascular invasion and positive hormone receptor status are associated with poorer response to neoadjuvant chemotherapy in breast cancer patients.

Keywords

Main Subjects